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Donor CD4+CD25+FOXP3+ regulatory T cells (Treg) are
capable of suppressing immune-mediated graft-versus-
leukemia (GvL) and graft-versus-host disease (GvHD)
responses. We undertook a dose-ﬁnding phase 1 study of
CD25-depleted donor lymphocyte infusions (DLI) to treat
post-transplantation relapse.
Methods: 24 subjects with disease relapse after HLA-
matched allogeneic transplantation (9 AML, 4 ALL, 4 HD, 2
MDS, 2 NHL) were enrolled. Patients had no evidence of
GvHD, were on no systemic immunosuppressants, and had
received no salvage chemotherapy in the 4 weeks preceding
DLI. Donor lymphocytes were CD25+ depleted via the Clin-
iMACS system (Miltenyi). Primary objectives were feasibility
and safety. Secondary objective was response.
Results - Feasibility: 3patients cameoff study for insufﬁcient
numbers of donor CD3+ cells or GvHD onset prior to DLI. In
the remainder, 10 had persistent or progressive disease, 7
were inPR, and4were inCRat studyentry. CD25-depletedDLI
doseswere 1x107 CD3+ cells/kg (level 1; n¼5) and 3x107 CD3+
cells/kg (level 2; n¼16). 8DLIswere fromunrelateddonors,13
from related donors. Median log-reductions of CD25+ and
CD4+CD25+FOXP3+Treg cells in the infusion products were
1.24 (range 0.72-7.75) and 2.10 (range 1.17-6.46), respectively.
Safety: 16 of 21 subjects were evaluable for toxicity. In 3
evaluable subjects at DLI Level 1, there were no DLTs. Dose
Level 2 was the MTD, with 1 case of fatal acute GvHD in 13
evaluable subjects.Amongall subjects, ratesofacuteorchronic
GvHD were 19% by 8 weeks and 38% by 1 year following DLI.
Response: Median follow-up is 29.5 months. All subjects at
Dose level 1 had progressive disease at 8 weeks; 1 experi-
enced extensive chronic GvHD. At Dose level 2, 8 subjects
(50%) had a response (1 PR, 7 CR), including 6 who had
evidence of disease at DLI. 6 subjects, including 5 responders,
manifested GvHD by day 100. 1 year survival was 8/16 (50%)
in the MTD cohort, with 4 of the initial 8 week responders
still in CR. Median survival was 15.4 months.
Conclusions: Use of CD25+ Treg depleted DLI appears
feasible, safe and capable of inducing GvL without excessive
GvHD in hematologic malignancies relapsed after allo-
transplantation. Its safety and preliminary efﬁcacy is prom-
ising but needs future prospective evaluation.Table 1
BLNK and Syk are increased in B cells from patients with cGVHD
Phenotype BLNK (MFI)
Median  SE
P-value Syk (MFI)
Median  SE
P-value
Without
cGVHD
(n¼6)
3.67  0.14 13.85  0.28
With cGVHD
(n¼4)
4.52  0.15 0.005 16.50  1.20 0.013
cGVHD, chronic GVHD; MFI, Mean Fluorescence Intensity.GVH/GVL ORAL
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In previous work, we found that CD27+ B cells from
patients with chronic GVHD (cGVHD) are metabolically
active and capable of constitutive IgG production via BAFF-
associated pathways. As B Cell Receptor (BCR) signaling is
vital for B cell survival and activation, we hypothesized that
antigen engagement of BCR confers distinct signaling in
potentially pathologic CD27+ B cells in human cGVHD. We
ﬁrst aimed to identify candidate genes using pathway-
focused mRNA expression proﬁling of highly puriﬁed CD27+
and CD27- B cell populations from 3 patients with cGVHD
and 3 healthy individuals. A unique array signature was
identiﬁed, conﬁrming that circulating CD27+ B cells in
cGVHD are distinct from healthy 'memory' B cells. Of the 89
genes examined, 3 transcripts were signiﬁcantly increased in
CD27+ B cells from patients with cGVHD compared to
healthy individuals. B-cell linker protein (BLNK), down-
stream of BCR ligation, was signiﬁcantly increased 5.5 fold
(p¼0.01) in CD27+ B cells from patients with cGVHD
compared to CD27+ B cells in healthy individuals. BLNK was
also increased 5-fold (p¼0.001) in CD27- B cells from
patients with cGVHD compared to CD27- B cells from healthy
individuals. Intracellular ﬂow cytometry veriﬁed that stim-
ulation of BCR resulted in increased expression of BLNK
protein in 3 healthy individuals at 36 (p¼0.01) and 60
(p¼0.03) hours. To extend these ﬁnding to patients with
cGVHD compared to patients without cGVHD we studied
puriﬁed, un-manipulated CD19+ B cells from 10 HSCT
patients who were >12 months post-transplant and off high
dose steroid. cGVHD (n¼4) B cells had signiﬁcantly increased
protein expression of BLNK (p¼0.005) compared to B cells
from patients without cGVHD (n¼6). The protein kinase Syk,
upstream of BLNK, was also signiﬁcantly increased in B cells
from cGVHD patients (p¼0.01) compared to B cells from
patients without disease. These data suggest that B cells in
cGVHD are hyper-responsive to antigen (Table 1). To deter-
mine if B cells trafﬁc to lesional tissue, liver biopsies were
immunohistochemically analyzed in 3 patients with cGVHD.
Two of 3 patients with disease had detectable CD27+ and
CD27- B cells in the liver while 2 reference biopsies from
acute hepatitis patients, without cGVHD, did not. This afﬁrms
that BCR-activated B cells can be found at cGVH disease sites.
Increased expression of BLNK and Syk in B cells from patients
MMF
(n¼117)
Placebo
(n¼119)
P value
GvHD free survival at
day 56
61% (52-70%) 52% (43-61%) 0.78 *
CGvHD at 6 mo 24% (16-32%) 27% (18-35%) 0.69 y
Non relapse mortality
at 6 mo
16% (9-22%) 20% (13-28%) 0.83 y
Overall survival at 6 mo 71% (62-79%) 74% (65-81%) 0.25z
* Chi-square test.
y Gray's test.
z Log-rank test.
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contribute to the pathophysiology of cGVHD. Thus, small
molecule inhibitors of Syk may represent a potential thera-
peutic option for patients with cGVHD.
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Steroids are accepted standard primary therapy for
aGvHD, but durable responses are infrequent. A prior trial
conducted by the BMT CTN (0302) tested the addition of 1 of
4 agents to steroids as initial therapy and found mycophe-
nolate mofetil (MMF) to be the most promising for further
investigation. In this context, a phase III, multi-center
randomized trial BMT CTN 0802, sponsored by the NHLBI
and NCI, was initiated to test the addition of MMF/placebo to
steroids as initial therapy for aGvHD. Patients with any grade
of newly diagnosed aGvHD were eligible if they required
systemic therapy. The primary study objective was GvHD
free survival at day 56 after initiation of therapy. All patients
received prednisone at 2 mg/kg/day (or equivalent) with
either MMF (1000mg PO/IV q8h or 20 mg/kg for patients
<60kg) or placebo. Taper of steroids was allowed no sooner
than 3 days into study therapy, at the discretion of the
treating physician, but the protocol required treatment with
prednisone at a dose of at least 0.25 mg/kg/day of prednisone
until day 28. MMFwas continued until day 56 or until steroid
discontinuation if sooner. Patients who developed aGvHD
while on MMF prophylaxis or after unplanned DLI were
excluded. Patients who had previously received MMF for
prophylaxis were eligible if they had not received any MMF
in the previous week. All patients needed to be engrafted.
The study speciﬁed a futility rule for GVHD free survival at
day 56 and the rule was met at a planned interim analysis
after 236 patients (out of 372) were enrolled from 36 centers:
117 toMMF,119 to placebo. Baseline characteristics werewell
balanced between treatment groups. Grade of GvHD atrandomizationwas I/II (65%), III (28%) and IV (6%). GvHD free
survival at day 56 after randomization was: MMF 69 pts
(60.5%; 95% CI 51.6-69.5), placebo 60 pts (52.2%; 95% CI 43.0-
61.3) P ¼ .78. Chronic GvHD developed in 38 patients on
MMF: 6 month (mo) estimate: 23.7% (95% CI 15.9-31.6), and
39 patients on placebo: 6 mo estimate: 26.5% (95% CI 18.3-
34.7) P ¼ .69. Overall survival at 6 mo, EBV reactivation,
cumulative incidence of severe, life threatening, or fatal
infections were similar. Cytopenias were more common in
the MMF arm, while hyperglycemia was more common in
the placebo arm. Cumulative incidence estimates for non
relapse mortality at 6 mo was similar in both arms: MMF
15.5% vs. placebo 20.1%. p¼0.83. Estimated 6 mo overall
survival was 71.3% forMMFand 73.8% for placebo P¼ .25. The
addition of MMF to steroids as ﬁrst line therapy for patients
with aGvHD does not result in improved GvHD free survival
compared to treatment with steroids alone.
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Atorvastatin (ATOR) is a potent immunomodulatory agent
that holds promise as a novel and safe agent for aGVHD
prophylaxis. In murine models ATOR administration to both
donor and recipient mice, prevented aGVHD by inhibiting
donor T-cell proliferation, inducing TH-2 polarization, and by
inhibiting recipient antigen presenting cell function.
We conducted a phase II study (NCT01175148) to evaluate
the safety and efﬁcacy of ATOR administration for aGVHD
prophylaxis, to both adult donors and recipients of MRD
alloHCT. As aGVHD prophylaxis, ATOR (40mg/day PO) was
administered to sibling donors, starting 14-28 days before
the anticipated 1st day of stem cell collection. In alloHCT
recipients aGVHD prophylaxis consisted of tacrolimus,
micro-dose methotrexate and ATOR (40mg/day) adminis-
tered from day -14 to day +180. Ex vivo or in vivo T-cell
depletion was not permitted. Primary outcomes were rate of
grade (Gr) II-IV aGVHD at day 100 and safety of ATOR
administration to alloHCT donors/recipients. We tested the
null hypothesis H0: p35%, vs. the alternate H1: p15%;
where p is the probability of Gr II-IV aGVHD at day 100.
